Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Phase 1 Completed 32 enrolled H. Lee Moffitt Cancer Center and Research Institute Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if the addition of the investigation drug called pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can help with controlling the growth of tumors, in participants with recurrent high grade glioma.

Timeline

Start: 2015-07-28
Primary completion: 2018-09-13
Completion: 2021-08-09

Publications

Bruningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2021 Oct 12;11(1):20219. doi: 10.1038/s41598-021-99507-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	100 mg	Intravenous
Background	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Summary

Timeline

Publications

Drugs

Indications